Every 8-K that CervoMed (CRVO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CRVO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRVO filings page.
CervoMed Inc. reported second quarter 2026 results and development updates for neflamapimod, its lead drug for age-related brain disorders. The company highlighted plans to prioritize securing a strategic partnership to advance neflamapimod into a Phase 3 trial for dementia with Lewy bodies (DLB). Neflamapimod received an Innovation Passport Designation under the UK’s ILAP framework for DLB, and new analyses presented at AAIC 2026 reinforced its treatment effect in pure DLB and supported a 50 mg three-times-daily dose for the planned Phase 3 trial.
CervoMed completed two equity financings in June 2026 for aggregate gross proceeds of approximately $20.5 million. As of June 30, 2026, cash, cash equivalents and marketable securities were about $24.9 million, up from $20.9 million at year-end 2025, which the company believes will fund operations through the third quarter of 2027. For the quarter, there was no grant revenue versus $1.8 million a year earlier, R&D expenses were about $4.3 million, G&A expenses about $2.4 million, and net loss was roughly $6.6 million compared with $6.3 million in 2025.
CervoMed Inc. announced that its lead candidate neflamapimod has been granted an Innovation Passport, allowing entry into the United Kingdom’s Innovative Licensing and Access Pathway (ILAP) for development in dementia with Lewy bodies (DLB). ILAP is designed to accelerate time to market and facilitate patient access through coordinated input from the MHRA, NHS and health technology assessment bodies.
Neflamapimod is an oral small molecule that selectively inhibits the alpha isoform of p38 MAP kinase to target neuroinflammation and synaptic dysfunction. It has been generally well tolerated across more than 800 Phase 1 and 2 participants and showed consistent signals of efficacy in the 91-patient Phase 2a AscenD-LB and 159-patient Phase 2b RewinD-LB DLB trials, improving cognitive and functional outcomes and key neurodegeneration biomarkers, with greatest benefits in patients without Alzheimer’s co-pathology. CervoMed has obtained alignment with the FDA and global regulators on a potential registration path in DLB, is focused on identifying a strategic partner and funding for a Phase 3 DLB trial, and is advancing Phase 2a programs in nfvPPA and ALS.
CervoMed Inc. reported new clinical, biomarker, and imaging analyses for its lead candidate neflamapimod in dementia with Lewy bodies, based on the 159-patient Phase 2b RewinD-LB trial and an additional Phase 2 study.
Exploratory RewinD-LB analyses linked neflamapimod’s treatment effects on the CDR-SB scale to patients with low plasma pTau181 and to those achieving higher plasma drug exposure, including a capsule batch that showed 0.17 vs 0.95 CDR-SB worsening compared with prior placebo in the same participants. MRI data indicated durable slowing of right basal forebrain atrophy and increased connectivity with the default mode network during neflamapimod treatment.
A PK-PD review identified a ~4 ng/mL trough plasma threshold associated with clinical and biomarker improvements, informing selection of a planned 50 mg three-times-daily dose expected to reach that level in most patients. A separate 24-week Phase 2 trial of 80 mg twice daily in 26 dementia with Lewy bodies patients met its primary safety, tolerability, and pharmacokinetic objectives and showed encouraging secondary clinical findings. CervoMed also reiterated plans to advance neflamapimod into Phase 3 in dementia with Lewy bodies, seek a strategic partner, and deliver additional Phase 2a data in non-fluent variant primary progressive aphasia and amyotrophic lateral sclerosis in 2026.
CervoMed Inc. has completed enrollment in its Phase 2a clinical study of neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA), a form of frontotemporal dementia with no approved treatments. The trial enrolled 25 participants on two oral dosing regimens over 24 weeks, followed by a 12‑week placebo‑controlled extension at leading U.S. academic centers.
Interim biomarker data from the study are scheduled to be presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston on November 16–19, 2026, with initial clinical data expected in the first quarter of 2027. Recent preclinical work published in Nature Neuroscience shows that p38α inhibition, including with neflamapimod, reversed axonal transport deficits in tau‑mutation FTD models, supporting the drug’s mechanistic rationale. Neflamapimod holds U.S. FDA Orphan Drug Designation for FTD, providing development and exclusivity benefits if approved.
CervoMed Inc. closed a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, raising gross proceeds of $10 million. The transaction was priced at-the-market under Nasdaq rules, with H.C. Wainwright & Co. acting as exclusive placement agent.
The company plans to use the net proceeds for working capital and general corporate purposes. The shares were issued under an effective Form S-3 shelf registration statement using a final prospectus supplement and accompanying prospectus filed with the SEC.
CervoMed Inc. entered into definitive agreements for a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, for aggregate gross proceeds of $10.0 million. The company plans to use the net proceeds for working capital and general corporate purposes.
H.C. Wainwright & Co. is acting as exclusive placement agent, receiving a 6.0% cash fee, a 1.0% management fee, specified expense reimbursements, and Placement Agent Warrants equal to 6.0% of the shares sold, exercisable at $5.00 per share. CervoMed agreed to a 30‑day lock‑up on most new equity issuances and a six‑month restriction on variable rate transactions, with customary exceptions. The new shares are being issued off an effective Form S‑3 shelf, while the Placement Agent Warrants and any pre‑funded warrants are being issued in a private placement with beneficial ownership limits of 4.99%, adjustable up to 9.99% after notice.
CervoMed Inc. reported that it received a notice of allowance from the United States Patent and Trademark Office for a new patent covering its drug candidate neflamapimod. The patent protects use of neflamapimod to treat dementia with Lewy bodies in patients without substantial Alzheimer’s disease-like tau pathology and is expected to provide intellectual property protection into 2042, strengthening long-term exclusivity for this indication.
CervoMed Inc. furnished an update that investor presentation materials about its business, clinical studies, development plans and financial position are available on its website under the Investors – Events and Presentations section. The company notes these materials may be used in meetings with investors, analysts and others.
The information is provided under Regulation FD as furnished, not filed, meaning it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other SEC filings unless specifically referenced.
CervoMed Inc. entered into a securities purchase agreement for a private placement of 3,360,377 units, each consisting of common stock or a pre-funded warrant plus Series B and Series C warrants, at $3.14 or $3.139 per unit, for anticipated gross proceeds of about $10.5 million.
The financing, which includes substantial participation from company insiders and institutional healthcare investors, could generate up to an additional $21.7 million if the Series B and Series C warrants are fully exercised for cash. CervoMed plans to use the funds to advance its lead drug neflamapimod and general corporate needs, and expects its cash runway, together with existing cash, to extend into the second quarter of 2027 while it pursues a strategic partnership to move neflamapimod into Phase 3 for dementia with Lewy bodies.
CervoMed Inc. held its 2026 Annual Meeting of Stockholders on June 8, 2026. Stockholders of record on April 17, 2026 could vote, with 9,258,719 shares of common stock outstanding as of that date.
Holders of 6,218,593 shares, or about 67.2% of shares outstanding, were present virtually or by proxy, so a quorum was achieved. All eight director nominees received the requisite plurality of votes and were elected. Three additional proposals, each requiring a majority of votes present and entitled to vote, were approved, including Proposal No. 2 with 6,092,751 votes for and Proposal No. 3 and Proposal No. 4 with more votes for than against.
CervoMed Inc. reported first-quarter 2026 results, including cash, cash equivalents and marketable securities of $12.9 million as of March 31, 2026. This compares to $20.9 million as of December 31, 2025, and the company expects this cash to fund operations into the third quarter of 2026.
For the quarter, CervoMed recorded no grant revenue versus approximately $1.9 million a year earlier, reflecting completion of its RewinD-LB trial and the end of related grant funding. Research and development expenses were about $5.1 million, up from $4.8 million, while general and administrative expenses rose to roughly $3.0 million from $2.4 million.
Net loss widened to approximately $8.0 million from $4.9 million, driven mainly by the grant revenue decline and higher operating costs. On the clinical side, the company highlighted extensive neflamapimod data in dementia with Lewy bodies and alignment with regulators on the final design of a planned Phase 3 trial, which it aims to start in the second half of 2026, subject to financing.
CervoMed Inc. reported new brain imaging data from its Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), presented at the 2026 AAN Annual Meeting. The analyses showed neflamapimod increased basal forebrain volume and functional connectivity compared with placebo, suggesting disease-related brain changes might be partly reversible.
The company highlights alignment with preclinical work and prior blood biomarker results, supporting the idea that neflamapimod may act on underlying DLB biology rather than just symptoms. CervoMed plans a global, pivotal Phase 3 DLB trial in the second half of 2026, subject to securing sufficient financing.
CervoMed Inc. is providing a detailed update on its lead drug candidate neflamapimod for dementia with Lewy bodies (DLB). The company is presenting new MRI analyses from the 159-patient Phase 2b RewinD-LB trial, global regulatory discussions, and a finalized Phase 3 trial design at the 2026 Lewy Body Dementia Association Annual Meeting.
Neflamapimod’s MRI data suggest a potential positive effect on basal forebrain atrophy and functional connectivity, and blood biomarker data (plasma GFAP) appear responsive to treatment. CervoMed plans to initiate a global, pivotal Phase 3 DLB trial in the second half of 2026, subject to available funding, while also highlighting prior Phase 2a and 2b results showing clinical and biomarker signals.
CervoMed Inc. filed a current report describing an investor presentation that has been made available on its website under the “Investors – Events and Presentations” section. Company representatives may use this material, with possible non‑material modifications, in meetings and conferences with investors and analysts.
The company emphasizes that the presentation is summary information meant to be read together with its other SEC filings and public announcements. The information in this report is being furnished under Item 7.01 and is not deemed “filed” for purposes of the Securities Exchange Act, nor incorporated by reference into other filings unless specifically referenced.
CervoMed reported new analyses from its Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB). Patients with lower plasma pTau181 levels, indicating fewer with Alzheimer’s co-pathology, showed greater clinical benefit on key measures such as CDR-SB and ADCS-CGIC.
The company will use a plasma pTau181 enrichment cutoff of <21 pg/mL in its planned global Phase 3 DLB trial, aiming to enroll mainly “pure” DLB patients. PK/PD analyses focused on this population support the planned 50mg TID dosing regimen. CervoMed plans to start Phase 3 in the second half of 2026, subject to available funding.
CervoMed Inc. reported fourth quarter and full year 2025 results and highlighted progress for its lead drug neflamapimod in dementia with Lewy bodies (DLB) and other brain disorders. The company reported positive Phase 2b RewinD-LB data and reached alignment with U.S. and global regulators on a planned Phase 3 trial design, formulation, dose, and dosing regimen in DLB.
As of December 31, 2025, CervoMed had approximately $20.9 million in cash, cash equivalents and marketable securities, down from $38.9 million a year earlier, and believes this will fund operations for approximately six months from the date of the release. Grant revenue declined to about $4.0 million in 2025 from $9.7 million in 2024 due to completion of the RewinD-LB trial phases.
Research and development expenses rose to roughly $21.8 million from $18.8 million, driven by manufacturing improvements, batch-related work from RewinD-LB, and new trials in ischemic stroke recovery and primary progressive aphasia. General and administrative expenses increased to about $10.5 million from $9.2 million, and net loss widened to approximately $27.0 million from $16.2 million.
CervoMed Inc. announced completion of a Phase 1 healthy volunteer study evaluating a new, stable crystal form of its lead drug candidate neflamapimod and used the results to select the dose for its planned Phase 3 trial in dementia with Lewy bodies (DLB).
The company plans to use a 50mg three-times-daily regimen of the stable crystal form in Phase 3 to match the plasma drug levels associated with the clinically active batch from its prior RewinD-LB Phase 2b trial. Management highlights that a controlled manufacturing process now consistently produces the stable form, aiming to avoid past variability seen with less stable polymorphs.
CervoMed reiterates neflamapimod’s potential in DLB and other degenerative brain disorders based on earlier Phase 2 data and states it plans to initiate a global, pivotal Phase 3 DLB trial in the second half of 2026, subject to available funding.
CervoMed Inc. announced that its lead drug candidate, neflamapimod, has been selected for inclusion in the UK-based EXPERTS-ALS platform, which rapidly tests potential treatments for amyotrophic lateral sclerosis (ALS) using biomarker-based trials. This will be the first clinical evaluation of neflamapimod in ALS.
Neflamapimod, an oral small molecule that crosses the blood–brain barrier and selectively inhibits p38 MAP kinase, will initially be studied in approximately 35 ALS participants for 18–24 weeks, with possible expansion to up to 80 patients. The trial will measure changes in blood neurofilament light chain, a marker linked to neuroaxonal damage and ALS progression, and include clinical and survival endpoints.
Trial costs in EXPERTS-ALS are funded by the UK National Institute for Health and Care Research and leading motor neuron disease charities, while CervoMed continues to focus on dementia with Lewy bodies (DLB) and plans a global Phase 3 DLB trial in the second half of 2026, subject to available funding.
CervoMed Inc. reported that it has made an investor presentation available on its website under the “Investors – Events and Presentations” section. Company representatives may use this presentation in meetings and conferences with investors, analysts and others, with possible non-material updates over time.
The presentation is described as summary information meant to be read together with CervoMed’s other SEC filings and public announcements. The company states it has no obligation to update the presentation except as required by law, and clarifies that the information is being furnished under Regulation FD rather than filed, so it is not subject to certain Exchange Act liabilities nor automatically incorporated into other securities filings.
CervoMed Inc. furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference. The disclosure is provided under Item 2.02 and is being furnished, not deemed “filed” for purposes of Section 18 of the Exchange Act. CervoMed’s common stock trades on the NASDAQ Capital Market under the symbol CRVO.
CervoMed (CRVO) furnished an 8-K stating it received written feedback from the U.S. Food and Drug Administration aligning on key aspects of its proposed Phase 3 clinical trial of neflamapimod for patients with dementia with Lewy bodies. The company disclosed this via a press release furnished under Regulation FD.
Selected sections of the press release—covering the initial overview, “Phase 3 Trial Design and Regulatory Alignment,” and part of “Advancing Towards Registration”—are incorporated by reference under Other Events. The 8-K notes the press release is furnished, not filed, under the Exchange Act.
CervoMed Inc. appointed David Quigley to its Board of Directors. The Board expanded from seven to eight members, and Quigley will serve until the next annual meeting. He brings over 25 years at McKinsey, including roles leading Private Capital and Life Sciences practices.
In connection with his appointment, Quigley received a stock option for 16,200 shares at an exercise price of $7.02, vesting in 36 equal monthly installments beginning October 31, 2025, under the 2025 Equity Incentive Plan. He will also receive standard non-employee director cash and equity compensation and entered into the company’s standard director and officer indemnification agreement. Quigley will not serve on any standing committees.
CervoMed Inc. furnished a Regulation FD update, noting that an investor presentation is available on its website under “Investors – Events and Presentations.” Company representatives may use the materials periodically in meetings and conferences.
The information is being furnished, not filed, and may be updated at management’s discretion as warranted by law. The filing also lists Exhibit 104, the cover page interactive data file embedded in Inline XBRL.
CervoMed Inc. furnished an update on its lead program by sharing new data from the RewinD-LB Phase 2b clinical trial of neflamapimod in patients with dementia with Lewy bodies. The company issued a press release and also posted a detailed investor presentation on its website under “Investors – Events and Presentations,” which covers business, clinical studies, development plans and financial position along with the new trial results. This information is provided as a Regulation FD disclosure and is treated as “furnished,” not “filed,” and is also incorporated by reference into an other-events section of this report.
CervoMed Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference into Item 2.02, and the filing states that the information is being furnished under Item 2.02 rather than filed for purposes of Section 18 of the Exchange Act. Item 9.01 lists Exhibits 99.1 (the press release) and 104 (cover page interactive data file).
CervoMed (NASDAQ:CRVO) filed an 8-K (Item 5.07) reporting voting results from its June 23 2025 Annual Meeting.
With 64.5% of shares represented, stockholders approved all four proposals: (1) election of seven directors; (2) ratification of RSM US LLP as 2025 auditor (5,571,505 for, 25,008 against); (3) advisory endorsement of 2024 executive pay (3,891,229 for, 33,195 against); and (4) adoption of the 2025 Equity Incentive Plan (3,798,568 for, 137,758 against). No other material changes, governance shifts, or financial impacts were disclosed.